Aug 28,2018

University Hospital of Zurich chooses Kaiku Health to improve the quality of care delivered to urological cancer patients

University Hospital of Zurich (USZ), one of the largest and most eminent teaching hospitals in Europe with approximately 1 500 physicians and scientists, selected Kaiku Health to automate patient-reported outcomes data collection from prostate and testicular cancer patients.

COLLABORATION PARTNERSHIP

#product & service

#mobile app

#rpm

View Analyst & Ambassador Comments
Go to original news
May 30,2018

Kaiku Health follow-up algorithm for cancer patients treated with immunotherapy enters a multi-center clinical trial

A novel follow-up algorithm for cancer immunotherapy, developed by digital health company Kaiku Health, is undergoing clinical validation in a multi-center trial conducted at Oulu University Hospital, Turku University Hospital and Docrates Cancer Center in Finland.

PRODUCT

#software

View Analyst & Ambassador Comments
Go to original news
Mar 01,2018

Patient experience, efficiency and cost effects of digital patient monitoring evaluated at the new study by Helsinki University Hospital

Urology department of Helsinki University Hospital has started a new research project ePRO-PCaRP/RT* evaluating patient experience, efficiency and cost effects of digital patient monitoring among prostate cancer patients. Kaiku Health application and an electronic questionnaire is used to evaluate the patient’s quality of life. Over 600 prostate cancer patients treated with both surgery and radiotherapy will be invited to participate in the research. Duration of this randomized phase III trial is approximately two years and the results will be published in relevant scientific journals

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 09,2017

Kaiku Health expands rapidly to European cancer centers

In Germany, Kaiku® Health is implemented for electronic patient follow-up at two new cancer clinics located in Nuremberg and Fürth. In Sweden, Kaiku Health –platform is used for digital collection of research data in a national phase 4 clinical trial coordinated from Gothenburg. “Our digital platform has already supported the healthcare of over 20 000 people globally. These new European clients are further accelerating our international growth during 2017 and beyond. Kaiku Health will be supporting a rapidly growing number of patients and their quality of lives,” says Lauri Sippola, CEO and Co-founder of Netmedi Ltd.

PRODUCT

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 25,2016

Netmedi launches a digital solution for immuno-oncology follow-up at ASCO

Finnish health technology company Netmedi has developed an innovative digital platform, Kaiku® Health IO, for the follow-up of patients treated with immune checkpoint inhibitors. The solution is about to enter multi-center clinical validation phase and has already attracted significant interest among a number of leading oncology clinics. Kaiku® Health IO provides a solution for enhanced management of immune-related adverse events, supporting patients and the care team throughout treatment and follow-up. Netmedi will launch Kaiku® Health IO Early Access Program at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 4th 2016.

PRODUCT

#rpm

View Analyst & Ambassador Comments
Go to original news
Jun 20,2016

Netmedi starts cooperation with the German HELIOS Clinics

Netmedi has started a cooperation with the helios.hub in Berlin as a first step to apply Kaiku Health platform for the digital follow-up of cancer patients during their therapy and recovery at the cancer clinics of the HELIOS Kliniken in Germany. helios.hub is the eHealth accelerator of the HELIOS Kliniken, the largest privately owned clinic chain in Germany. helios.hub supports start-ups to develop, test and bring digital applications into the clinical practice.

COLLABORATION PARTNERSHIP

#r&d

#rpm

View Analyst & Ambassador Comments
Go to original news
Aug 17,2016

Digital calculator provides the estimated risk for GIST recurrence

Finnish digital technology company Netmedi has developed an online calculator that significantly improves the process of evaluating the risk of GIST (Gastrointestinal Stromal Tumor) recurrence and the need for additional treatment after surgery. The calculator is based on a risk analysis model published in 2012 by HUCH Cancer Center and Aalto University and is intended to be used in cancer care and research.

PRODUCT

#software

View Analyst & Ambassador Comments
Go to original news
Jan 01,2022

Blue Note Therapeutics Receives Breakthrough Device Designation for Prescription-only Digital Therapeutic for Acute Myeloid Leukemia

Blue Note Therapeutics, a prescription digital therapeutics company dedicated to easing the burden of cancer and improving outcomes, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for BNT200. BNT200 is a first-of-its-kind prescription-only digital therapeutic to treat anxiety and depressive symptoms in adults with acute myeloid leukemia (AML) who are hospitalized for a regimen of high-intensity induction chemotherapy.

REGULATORY FDA

#pdt

View Analyst & Ambassador Comments
Go to original news
Jan 06,2022

Voluntis and AliveCor Partner to Advance Management of Atrial Fibrillation for Patients with Cancer

Voluntis, an Aptar Pharma company and leader in digital therapeutics, today announced that it has entered into a partnership agreement with AliveCor, Inc. (AliveCor), a leading innovator in FDA-cleared personal electrocardiogram (ECG) technology. Under the collaboration, AliveCor’s KardiaMobile device will be integrated with Theraxium, Voluntis’ regulated platform for digital therapeutics (DTx), to help address the challenges associated with cardiotoxicity management for patients undergoing cancer treatment and facilitate remote self-monitoring for atrial fibrillation (AFib).

COLLABORATION PARTNERSHIP

#product & service

#connected device

View Analyst & Ambassador Comments
Go to original news
Feb 01,2022

Blue Note Therapeutics Enters Licensing Agreement with University of Sydney for ConquerFear, a Cancer Survivorship Intervention

Blue Note Therapeutics, a prescription digital therapeutics company dedicated to easing the burden of cancer and improving outcomes, today announced that the company has entered into an agreement with the University of Sydney for the exclusive licensing of ConquerFear, a metacognitive intervention to teach patients effective ways to cope with the fears associated with the potential for cancer recurrence. Effective immediately, Blue Note has licensing rights to ConquerFear for the purposes of creating a digital technology for the treatment of psychological distress related to fear of cancer recurrence (FCR).

COLLABORATION PARTNERSHIP

#product & service

#pdt

#coaching

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY